Hepatitis B virus genotype has no impact on hepatitis B e antigen seroconversion after lamivudine treatment

World J Gastroenterol. 2003 Dec;9(12):2695-7. doi: 10.3748/wjg.v9.i12.2695.


Aim: To investigate the association of hepatitis B virus (HBV) genotype and HBeAg seroconversion after nucleotide analogue treatment.

Methods: Chronic hepatitis B patients receiving lamivudine followed up for at least 6 months post-treatment were studied. Consecutive treatment-naïve patients who were prospectively followed up in the clinic for at least 18 months were studied as controls. HBeAg seroconversion was defined as loss of HBeAg, appearance of anti-HBe and normalization of alanine aminotransferase for at least 6 months.

Results: Thirty-five patients on lamivudine and 96 control patients followed up for 39 (18-49) months were studied. Lamivudine was given for 12 (10-18) months, and patients were followed up for 15 (6-34) months after drug cessation. Genotype B and C HBV were found in 43 and 88 patients and HBeAg seroconversion occurred in 12 (28%) and 16 (18%) patients, respectively (P=0.30). There was no difference in HBeAg seroconversion between patients infected by genotype B and C HBV in the control (35% vs 21%, P=0.25) and lamivudine-treated (14% vs 10%, P=1.00) groups.

Conclusion: HBeAg seroconversion after treatment by lamivudine was not influenced by the HBV genotype.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Alanine Transaminase / blood
  • Antiviral Agents / administration & dosage
  • Antiviral Agents / blood
  • Antiviral Agents / pharmacokinetics*
  • Base Sequence
  • Child
  • Female
  • Genotype
  • Hepatitis B e Antigens / blood*
  • Hepatitis B virus / drug effects
  • Hepatitis B virus / genetics*
  • Hepatitis B, Chronic / drug therapy*
  • Humans
  • Lamivudine / administration & dosage
  • Lamivudine / blood
  • Lamivudine / pharmacokinetics*
  • Male
  • Middle Aged
  • Reference Values
  • Time Factors


  • Antiviral Agents
  • Hepatitis B e Antigens
  • Lamivudine
  • Alanine Transaminase